LIVIVO - Search results -

Search results

Result 1 - 10 of total 2447

Search options

Article ; Online: Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.

Alatorre-Moreno, Edith Viridiana / Saldaña-Cruz, Ana Miriam / Pérez-Guerrero, Edsaúl Emilio / Morán-Moguel, María Cristina / Contreras-Haro, Betsabé / López-de La Mora, David Alejandro / Dávalos-Rodríguez, Ingrid Patricia / Marín-Medina, Alejandro / Rivera-Cameras, Alicia / Balderas-Peña, Luz-Ma Adriana / Gómez-Ramos, José Juan / Cortés-Sanabria, Laura / Salazar-Páramo, Mario

Genes

2024 Volume 15, Issue 4

Abstract: ... Results: The GG genotype of CYP3A5-6986 A/G polymorphism is associated with TAC pharmacokinetic ... showed that CYP3A5-6986 A/G GG genotype is associated with a four-fold increase in the likelihood ...

Abstract	Tacrolimus (TAC) is an immunosuppressant drug that prevents organ rejection after transplantation. This drug is transported from cells via P-glycoprotein (ABCB1) and is a metabolic substrate for cytochrome P450 (CYP) 3A enzymes, particularly CYP3A4 and CYP3A5. Several single-nucleotide polymorphisms (SNPs) have been identified in the genes encoding Methods: Forty-six kidney transplant recipients (KTR) receiving immunosuppressive treatment with TAC in different combinations were included. CYP3A4, CYP3A5, and Results: The GG genotype of CYP3A5-6986 A/G polymorphism is associated with TAC pharmacokinetic variability OR 4.35 (95%CI: 1.13-21.9; Conclusion: The findings of this study of the Mexican population showed that CYP3A5-6986 A/G GG genotype is associated with a four-fold increase in the likelihood of encountering a TAC concentration of more than 15 ng/dL. The co-occurrence of the CYP3A5-6986GG genotype and the use of drugs that increase TAC concentration correlates with a nine-fold increased risk of experiencing a TAC at a level above 15 ng/mL. Therefore, these patients have an increased susceptibility to TAC-associated toxicity.
MeSH term(s)	Humans ; Cytochrome P-450 CYP3A/genetics ; Kidney Transplantation/adverse effects ; Tacrolimus/blood ; Tacrolimus/pharmacokinetics ; Tacrolimus/administration & dosage ; ATP Binding Cassette Transporter, Subfamily B/genetics ; Female ; Male ; Polymorphism, Single Nucleotide/genetics ; Adult ; Mexico ; Immunosuppressive Agents/pharmacokinetics ; Immunosuppressive Agents/blood ; Immunosuppressive Agents/administration & dosage ; Middle Aged ; Genotype ; Graft Rejection/genetics
Chemical Substances	Cytochrome P-450 CYP3A (EC 1.14.14.1) ; Tacrolimus (WM0HAQ4WNM) ; ATP Binding Cassette Transporter, Subfamily B ; ABCB1 protein, human ; CYP3A4 protein, human (EC 1.14.14.55) ; CYP3A5 protein, human (EC 1.14.14.1) ; Immunosuppressive Agents
Language	English
Publishing date	2024-04-16
Publishing country	Switzerland
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	2527218-4
ISSN	2073-4425 ; 2073-4425
ISSN (online)	2073-4425
ISSN	2073-4425
DOI	10.3390/genes15040497
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Remdesivir-COVID-19: drug interactions in dentistry.

Gómez-Moreno, G

European review for medical and pharmacological sciences

2020 Volume 24, Issue 18, Page(s) 9739–9743

Abstract: Objective: Remdesivir is a nucleotide analogue prodrug that inhibits viral RNA polymerases. It has been recognized recently as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5). We aimed at determining which drugs ...

Abstract	Objective: Remdesivir is a nucleotide analogue prodrug that inhibits viral RNA polymerases. It has been recognized recently as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5). We aimed at determining which drugs used in dentistry interact with Remdesivir in order to avoid adverse reactions that may worsen the condition of patients with COVID-19. Materials and methods: A literature review was conducted to identify potential drug interactions between remdesivir (used in the treatment of COVID-19) and drugs prescribed in dentistry. The search was made in the databases PubMed and MEDLINE and official websites using key terms remdesivir, drug interactions and dentistry for articles published up to 31st July 2020. Results: According to the articles reviewed, a total of 279 drugs interact with Remdesivir. Two major interactions have been reported, 277 moderate drug interactions, and one with alcohol/food. The drug interactions involving drugs prescribed in dentistry are all moderate drug interactions and are (according to drug group): (1) antibiotics: azithromycin, clavulanate, doxycycline, erythromycin, levofloxacin; (2) antifungals: clotrimazole, fluconazole, itraconazole, ketoconazole; (3) non-steroidal anti-inflammatories (NAIDS): celecoxib diclofenac, etodolac, flurbiprofen, ibuprofen, ketoprofen, ketorolac, mefenamic acid, naproxen, piroxicam. Conclusions: It is clinically necessary for oral health professionals to be aware of possible drug interactions that may occur between remdesivir and drugs commonly prescribed in dentistry in order to prevent adverse reactions that may even endanger the life of a patient with COVID-19.
MeSH term(s)	Adenosine Monophosphate/adverse effects ; Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/adverse effects ; Alanine/analogs & derivatives ; Alanine/therapeutic use ; Antiviral Agents/adverse effects ; Antiviral Agents/therapeutic use ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/drug therapy ; Dentistry ; Drug Interactions ; Humans ; Pandemics ; Pneumonia, Viral/drug therapy ; SARS-CoV-2
Chemical Substances	Antiviral Agents ; remdesivir (3QKI37EEHE) ; Adenosine Monophosphate (415SHH325A) ; Alanine (OF5P57N2ZX)
Keywords	covid19
Language	English
Publishing date	2020-10-05
Publishing country	Italy
Document type	Journal Article ; Review
ZDB-ID	605550-3
ISSN	2284-0729 ; 1128-3602 ; 0392-291X
ISSN (online)	2284-0729
ISSN	1128-3602 ; 0392-291X
DOI	10.26355/eurrev_202009_23065
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1887: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Remdesivir-COVID-19: drug interactions in dentistry

Gómez-Moreno, G.

Eur Rev Med Pharmacol Sci

Abstract: OBJECTIVE: Remdesivir is a nucleotide analogue prodrug that inhibits viral RNA polymerases It has been recognized recently as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) We aimed at determining which drugs ... ...

Abstract	OBJECTIVE: Remdesivir is a nucleotide analogue prodrug that inhibits viral RNA polymerases It has been recognized recently as a promising antiviral drug against a wide array of RNA viruses (including SARS/MERS-CoV5) We aimed at determining which drugs used in dentistry interact with Remdesivir in order to avoid adverse reactions that may worsen the condition of patients with COVID-19 MATERIALS AND METHODS: A literature review was conducted to identify potential drug interactions between remdesivir (used in the treatment of COVID-19) and drugs prescribed in dentistry The search was made in the databases PubMed and MEDLINE and official websites using key terms remdesivir, drug interactions and dentistry for articles published up to 31st July 2020 RESULTS: According to the articles reviewed, a total of 279 drugs interact with Remdesivir Two major interactions have been reported, 277 moderate drug interactions, and one with alcohol/food The drug interactions involving drugs prescribed in dentistry are all moderate drug interactions and are (according to drug group): (1) antibiotics: azithromycin, clavulanate, doxycycline, erythromycin, levofloxacin;(2) antifungals: clotrimazole, fluconazole, itraconazole, ketoconazole;(3) non-steroidal anti-inflammatories (NAIDS): celecoxib diclofenac, etodolac, flurbiprofen, ibuprofen, ketoprofen, ketorolac, mefenamic acid, naproxen, piroxicam CONCLUSIONS: It is clinically necessary for oral health professionals to be aware of possible drug interactions that may occur between remdesivir and drugs commonly prescribed in dentistry in order to prevent adverse reactions that may even endanger the life of a patient with COVID-19
Keywords	covid19
Publisher	WHO
Document type	Article
Note	WHO #Covidence: #814893
Database	COVID19

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Details ▾

Article ; Online: Corrigendum to "Chronic melatonin treatment improves obesity by inducing uncoupling of skeletal muscle SERCA-SLN mediated by CaMKII/AMPK/PGC1α pathway and mitochondrial biogenesis in female and male Zücker diabetic fatty rats" [Biomed. Pharmacother. 172 (2024) 116314].

Salagre, D / Navarro-Alarcón, M / Villalón-Mir, M / Alcázar-Navarrete, B / Gómez-Moreno, G / Tamimi, F / Agil, A

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

2024 Volume 173, Page(s) 116411

Language	English
Publishing date	2024-03-07
Publishing country	France
Document type	Published Erratum
ZDB-ID	392415-4
ISSN	1950-6007 ; 0753-3322 ; 0300-0893
ISSN (online)	1950-6007
ISSN	0753-3322 ; 0300-0893
DOI	10.1016/j.biopha.2024.116411
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.198: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Chronic melatonin treatment improves obesity by inducing uncoupling of skeletal muscle SERCA-SLN mediated by CaMKII/AMPK/PGC1α pathway and mitochondrial biogenesis in female and male Zücker diabetic fatty rats.

Salagre, D / Navarro-Alarcón, M / Villalón-Mir, M / Alcázar-Navarrete, B / Gómez-Moreno, G / Tamimi, F / Agil, A

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

2024 Volume 172, Page(s) 116314

Abstract: Melatonin acute treatment limits obesity of young Zücker diabetic fatty (ZDF) rats by non-shivering thermogenesis (NST). We recently showed melatonin chronically increases the oxidative status of vastus lateralis (VL) in both obese and lean adult male ... ...

Abstract	Melatonin acute treatment limits obesity of young Zücker diabetic fatty (ZDF) rats by non-shivering thermogenesis (NST). We recently showed melatonin chronically increases the oxidative status of vastus lateralis (VL) in both obese and lean adult male animals. The identification of VL skeletal muscle-based NST by uncoupling of sarcoendoplasmic reticulum Ca
MeSH term(s)	Female ; Male ; Animals ; Rats ; AMP-Activated Protein Kinases ; Calcium-Calmodulin-Dependent Protein Kinase Type 2 ; Melatonin/pharmacology ; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha ; Rats, Zucker ; Diabetes Mellitus, Experimental ; Organelle Biogenesis ; Muscle, Skeletal ; Obesity/drug therapy ; Muscle Proteins ; Proteolipids
Chemical Substances	sarcolipin (145018-73-1) ; AMP-Activated Protein Kinases (EC 2.7.11.31) ; Calcium-Calmodulin-Dependent Protein Kinase Type 2 (EC 2.7.11.17) ; Melatonin (JL5DK93RCL) ; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha ; Muscle Proteins ; Proteolipids
Language	English
Publishing date	2024-02-22
Publishing country	France
Document type	Journal Article
ZDB-ID	392415-4
ISSN	1950-6007 ; 0753-3322 ; 0300-0893
ISSN (online)	1950-6007
ISSN	0753-3322 ; 0300-0893
DOI	10.1016/j.biopha.2024.116314
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ud II Zs.198: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pseudomembranous oral candidiasis resolved with a mouthwash containing 0.05% chlorhexidine + 0.05% cetylpyridinium chloride.

Gómez-Moreno, G / Valerón-Rodríguez, F

European review for medical and pharmacological sciences

2021 Volume 25, Issue 18, Page(s) 5725–5728

Abstract: A 50-year-old woman was referred to the clinic reporting oral discomfort during the previous month and plaques of a white removable slough. Diagnosis of pseudomembranous oral candidiasis was clinically confirmed. When the tongue and palatal mucosa were ... ...

Abstract	A 50-year-old woman was referred to the clinic reporting oral discomfort during the previous month and plaques of a white removable slough. Diagnosis of pseudomembranous oral candidiasis was clinically confirmed. When the tongue and palatal mucosa were wiped with gauze, the soft yellowish-white slough detached revealing the erythematous surface beneath. The patient also presented paranoid schizophrenia and severe depression, pulmonary emphysema, and two vertebral hernias. She was a smoker (10 cigarettes per day) with xerostomia that was being treated with: bupropion, reboxetine, quetiapine, trazadone clotiapine, pregabalin, fentanyl (patches), and alprazolam. To minimize the risk of potential drug interactions, a mouthwash containing 0.05% chlorhexidine + 0.05% cetylpyridinium chloride was prescribed three times a day for two weeks. At the end of the two weeks, the candidiasis had abated.
MeSH term(s)	Candidiasis, Oral/complications ; Candidiasis, Oral/drug therapy ; Candidiasis, Oral/pathology ; Cetylpyridinium/administration & dosage ; Chlorhexidine/administration & dosage ; Depression/complications ; Drug Interactions ; Female ; Humans ; Middle Aged ; Mouthwashes/administration & dosage ; Pulmonary Emphysema ; Schizophrenia/complications ; Treatment Outcome ; Xerostomia/complications
Chemical Substances	Mouthwashes ; Cetylpyridinium (CUB7JI0JV3) ; Chlorhexidine (R4KO0DY52L)
Language	English
Publishing date	2021-09-28
Publishing country	Italy
Document type	Case Reports ; Journal Article
ZDB-ID	605550-3
ISSN	2284-0729 ; 1128-3602 ; 0392-291X
ISSN (online)	2284-0729
ISSN	1128-3602 ; 0392-291X
DOI	10.26355/eurrev_202109_26790
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1887: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Short-term effectiveness prognostic factors after dexamethasone intravitreal implant in macular edema due to retinal vein occlusion.

Garay-Aramburu, Gonzaga / Gómez-Moreno, Ángela / Urcola, Aritz

European journal of ophthalmology

2021 Volume 32, Issue 3, Page(s) 1671–1679

Abstract: Introduction: The aim of this study was to describe functional and anatomical changes (best-corrected visual acuity [BCVA], central macular thickness [CMT], and central macular volume [CMV]) in patients with macular edema (ME) secondary to retinal vein ... ...

Abstract	Introduction: The aim of this study was to describe functional and anatomical changes (best-corrected visual acuity [BCVA], central macular thickness [CMT], and central macular volume [CMV]) in patients with macular edema (ME) secondary to retinal vein occlusion (RVO) treated with intravitreal dexamethasone implant (IDI) and identify its clinical predictors in a real-world setting. Methods: Data from 111 patients who underwent IDI to treat RVO-associated ME were retrospectively reviewed. Demographic, preoperative, and postoperative variables were assessed using a logistic regression analysis to determine predictors of visual and anatomical improvement. Results: Mean BCVA, CMT, and CMV improved from baseline after IDI ( Conclusion: This study confirmed the effectiveness of IDI to treat ME secondary to RVO and identified new predictive factors for two visual (⩾15 ETDRS letters gain and BCVA ⩾80 ETDRS letters) and two anatomical outcomes (>50% CMT and >15% CMV reduction).
MeSH term(s)	Cytomegalovirus Infections/complications ; Cytomegalovirus Infections/drug therapy ; Dexamethasone ; Diabetic Retinopathy/drug therapy ; Drug Implants/therapeutic use ; Glucocorticoids ; Humans ; Intravitreal Injections ; Macular Edema/diagnosis ; Macular Edema/drug therapy ; Macular Edema/etiology ; Prognosis ; Retinal Vein Occlusion/complications ; Retinal Vein Occlusion/diagnosis ; Retinal Vein Occlusion/drug therapy ; Retrospective Studies ; Treatment Outcome ; Visual Acuity
Chemical Substances	Drug Implants ; Glucocorticoids ; Dexamethasone (7S5I7G3JQL)
Language	English
Publishing date	2021-07-13
Publishing country	United States
Document type	Journal Article
ZDB-ID	1089461-5
ISSN	1724-6016 ; 1120-6721
ISSN (online)	1724-6016
ISSN	1120-6721
DOI	10.1177/11206721211032520
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3342: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Disease-Modifying Antirheumatic Drugs (DMARDs) and drug interactions in dentistry.

Muñoz-Martínez, C / Segura-Puertas, M / Gómez-Moreno, G

European review for medical and pharmacological sciences

2021 Volume 25, Issue 7, Page(s) 2834–2842

Abstract: Objective: Rheumatoid arthritis is a chronic autoimmune disease. Treatment aims to reduce and improve its signs and symptoms. Hence, Disease-Modifying Antirheumatic Drugs (DMARDs) are the treatment of choice. The objective of this study was to identify ... ...

Abstract	Objective: Rheumatoid arthritis is a chronic autoimmune disease. Treatment aims to reduce and improve its signs and symptoms. Hence, Disease-Modifying Antirheumatic Drugs (DMARDs) are the treatment of choice. The objective of this study was to identify potential interactions between DMARDs and the drugs most frequently prescribed in dentistry in order to avoid adverse reactions. Materials and methods: This literature review sets out to define possible adverse reactions provoked by pharmacological interactions between DMARDs and the drugs commonly prescribed in dentistry. A search was conducted in PubMed by searching the names of drugs used in dentistry, "drug interactions," "rheumatoid arthritis," and "dentistry", "hydroxychloroquine", "leflunomide", "methotrexate", "sulfasalazine", "adalimumab", "anakinra", "etanercept", "abatacept", "infliximab" and "rituximab". Results: It was found that most DMARDs show potential interactions with many drugs used in dentistry, including various antibiotics, analgesics, anesthetics, antifungals, and corticosteroids. Conclusions: It is clinically important for oral health clinicians to be aware of possible drug interactions between DMARDs and the drugs commonly prescribed in dentistry to prevent potential adverse reactions and avoid endangering the patient.
MeSH term(s)	Antirheumatic Agents/adverse effects ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Drug Interactions ; Humans
Chemical Substances	Antirheumatic Agents
Language	English
Publishing date	2021-04-20
Publishing country	Italy
Document type	Journal Article ; Systematic Review
ZDB-ID	605550-3
ISSN	2284-0729 ; 1128-3602 ; 0392-291X
ISSN (online)	2284-0729
ISSN	1128-3602 ; 0392-291X
DOI	10.26355/eurrev_202104_25536
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1887: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Impact of human leukocyte antigen molecules E, F, and G on the outcome of transplantation.

Pabón, M A / Navarro, C E / Osorio, J C / Gómez, N / Moreno, J P / Donado, A F / Pérez, H C / Lozano, E

Transplantation proceedings

2014 Volume 46, Issue 9, Page(s) 2957–2965

Abstract: ... HLA molecules (E, F, and G) have acquired relevance owing to their immunomodulatory properties and ... clinical outcomes in any of the studies. Elevated serum levels of HLA-G were associated with a lower ...

Abstract	Background: HLA class I molecules are divided into classic (Ia) and nonclassic (Ib). Nonclassic HLA molecules (E, F, and G) have acquired relevance owing to their immunomodulatory properties and possible repercussions for induction of tolerance in organ transplantation. The objective of this study was to identify the impact of these molecules on transplant success or failure. Methods: A systematic review of literature was performed with the use of MeSH terms in Pubmed. Clinical trials, randomized clinical trials, case-control studies, and reviews from the past 15 years were included. Results: HLA-E0103/E0103 genotype is associated with lower risk of graft-versus-host disease, decreased mortality, and greater disease-free survival after bone marrow transplantation. There were no significant associations between HLA-F and clinical outcomes in any of the studies. Elevated serum levels of HLA-G were associated with a lower incidence of rejection in hepatic and renal transplantation during the 1st year and lower T-cell response after bone marrow, liver, and kidney transplantation. Detection of mRNA of HLA-G1 was also associated with less graft rejection. Conclusions: Current literature suggests that nonclassic HLA Ib molecules play an important role in immunotolerance in organ transplantation; however, more studies are required to predict outcomes related to specific genotypes.
MeSH term(s)	Bone Marrow Transplantation/mortality ; Disease-Free Survival ; Genotype ; Graft Rejection/genetics ; Graft Rejection/immunology ; Graft vs Host Disease/genetics ; Graft vs Host Disease/immunology ; HLA-G Antigens/genetics ; HLA-G Antigens/immunology ; HLA-G Antigens/metabolism ; Histocompatibility Antigens Class I/genetics ; Histocompatibility Antigens Class I/immunology ; Histocompatibility Antigens Class I/metabolism ; Humans ; Immune Tolerance ; Kidney Transplantation/mortality ; Liver Transplantation/mortality ; Organ Transplantation/mortality ; Outcome Assessment, Health Care ; HLA-E Antigens
Chemical Substances	HLA-F antigens ; HLA-G Antigens ; Histocompatibility Antigens Class I
Language	English
Publishing date	2014-11-26
Publishing country	United States
Document type	Journal Article ; Review ; Systematic Review
ZDB-ID	82046-5
ISSN	1873-2623 ; 0041-1345
ISSN (online)	1873-2623
ISSN	0041-1345
DOI	10.1016/j.transproceed.2014.07.010
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 835: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Hepatitis B Virus and DNA Damage Response: Interactions and Consequences for the Infection.

Gómez-Moreno, Andoni / Garaigorta, Urtzi

Viruses

2017 Volume 9, Issue 10

Abstract: ... by viral and cellular factors, some of which remain still undefined. Key steps of HBV life cycle e.g ...

Abstract	Hepatitis B virus (HBV) is a major etiologic agent of acute and chronic hepatitis, and end-stage liver disease. Establishment of HBV infection, progression to persistency and pathogenesis are determined by viral and cellular factors, some of which remain still undefined. Key steps of HBV life cycle e.g., transformation of genomic viral DNA into transcriptionally active episomal DNA (cccDNA) or transcription of viral mRNAs from cccDNA, take place in the nucleus of infected cells and strongly depend on enzymatic activities provided by cellular proteins. In this regard, DNA damage response (DDR) pathways and some DDR proteins are being recognized as important factors regulating the infection. On one hand, HBV highjacks specific DDR proteins to successfully complete some of the steps of its life cycle. On the other hand, HBV subverts DDR pathways to presumably create a cellular environment that favours its replication. Direct consequences of these interactions are: HBV DNA integration into host chromosomal DNA, and accumulation of mutations in host chromosomal DNA that could eventually trigger carcinogenic processes, which would explain in part the incidence of hepatocellular carcinoma in chronically infected patients. Unravelling the interactions that HBV establishes with DDR pathways might help identify new molecular targets for therapeutic intervention.
Language	English
Publishing date	2017-10-19
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2516098-9
ISSN	1999-4915 ; 1999-4915
ISSN (online)	1999-4915
ISSN	1999-4915
DOI	10.3390/v9100304
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

To top

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Kategorien

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito